

Code No. 28069

**Anti-Rat  
LRG (128) Rabbit IgG Affinity Purify**Volume : 100 µg

---

**Introduction** : Among the diseases which should be distinguished from iNPH (idiopathic normal pressure hydrocephalus) of elderly people showing symptoms such as gait disorder and dementia, there are some neurodegenerative diseases such as Alzheimer's disease, FTLD (frontotemporal lobar degeneration) and disorder associated with Parkinson's disease. iNPH can be treated by ventriculo-peritoneal shunt (VP shunt), so a marker in spinal fluid which can distinguish it from neurodegenerative diseases in an early stage has been required. Arai, Miyajima *et al.* had identified the high level of leucine-rich alpha-2-glycoprotein (LRG) in cerebrospinal fluid of iNPH patients, and they reported that measurement of LRG would be useful for differential identification of iNPH.

This antibody shows positive signals with choroids plexus cells and cilia of ependymal cells of rat.

**Antigen** : Synthetic peptide of a part of Rat LRG (LVLRENQLQEASARWLQG)

**Purification** : Purified with antigen peptide

**Form** : Lyophilized product from 1 % BSA in PBS containing 0.05% NaN<sub>3</sub>

**How to use** : 1.0 mL deionized water will be added to the product (the conc. comes up 100 µg /mL)

**Stability** : Lyophilized product, 5 years at 2 – 8 °C  
: Solution, 2 years at –20 °C

**Application** : This antibody can be used for immunohistochemistry with formalin fixed paraffin embedded tissues by several techniques such as Avidin Biotin Complex (ABC) Method or used for immunofluorescent staining (e.g. Alexa488) with frozen section 30 µm thick . The optimal concentration is about 1-5 µg/mL however, the concentration should be optimized by each laboratory.  
: This antibody can be used for western blotting in concentration of 1 - 5 µg /mL.

**Specificity** : Rat LRG specific.

**Reference** : 1. Lins H, Wichart I, Bancher C, Wallesch CW, Jellinger KA, Rösler N. Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. *J Neural Transm.* 2004 Mar;111(3):273-80.  
2. Li X, Miyajima M, Mineki R, Taka H, Murayama K, Arai H. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. *Acta Neurochir (Wien).* 2006 Aug;148(8):859-64.

---

*For Non-Clinical Research Use Only*